We have published paper "BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization" in Nature Communictions.
We have published review H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development in Future Medicinal Chemistry.
We published development of potent BCL6 inhibitor in collaboration with groups from Cornell and University of Maryland.
David Rogawski defended his PhD thesis. Congratulations Dave!
We published paper "Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and Mixed Lineage Leukemia (MLL)" in the Journal of Medicinal Chemistry.
We determined structure of ZMIZ1 TPR domain and published paper in collaboration with Mark Chiang: The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia. Published in Immunity.
Our manuscript "Two loops undergoing concerted dynamics regulate activity of the ASH1L histone methyltransferase" has been published in Biochemistry.
Our study "Rational design of orthogonal multipolar interactions with fluorine in protein-ligand complexes" has been published in Journal of Medicinal Chemistry, selected as Editor's choice.
Felicia Gray defended her PhD thesis: "Dissecting Bmi1 protein-protein interactions through chemical biology". Congratulations Felicia!
We have published study demonstrating that menin-MLL inhibitors block activity of MLL fusion proteins in a mechanism independent on fusion partner. Published in Leukemia.
George Lund defended his PhD dissertation: "Targeting CDC25B-CDK2/CyclinA Activity Using Chemical Biology Approaches".
Our menin-MLL inhibitor program has been featured as cover story in BioCentury Innovations
Dr. Chinnaiyan's lab discovered role of menin and demonstrated efficacy of menin inhibitors in castrate resistant prostate cancer. Study published in Nature Medicine.
Our team work resulted in development of potent inhibitors of menin-MLL interaction with strong efficacy in animal models of leukemia. Published in Cancer Cell.
We have licensed menin-MLL inhibitors to Kura Oncology for further development.
Jola is co-author on study to develop small molecule inhibitors of CBFB-SMMHC: "A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice" published in Science.
We published review Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? in Immunological Reviews
Our study Inhibition of CDC25B Phosphatase Through Disruption of Protein-Protein Interaction has been published in ACS Chemical Biology.
Jola has been elected to the University of Michigan Medical School "League of Research Excellence". Congratulations to Jola!
Our study "The same site on LEDGF IBD domain represents therapeutic target for MLL leukemia and HIV" has been published in Blood.
George's publication "Solution NMR studies reveal no global flexibility in the catalytic domain of CDC25B" has been published in journal Proteins.
Congratulations to George!
Our review "Challenges and opportunities in targeting the menin-MLL interaction" has been published in Future Medicinal Chemistry
MSc in chemistry: Department of Chemistry; Wroclaw University of Technology; Poland
PhD in biochemistry: Department of Biochemistry and Molecular Biology; University of Wroclaw; Poland
Postdoctoral fellow: University of Virginia, Charlottesville, VA
Assistant Professor in the Department on Pathology, University of Michigan (since 2009)
American Cancer Society Research Scholar (2011)
Affiliations with graduate programs:
• Molecular and Cellular Pathology program
• Biophysics program
• Chemical Biology program
• Structure-function studies of proteins involved in development of acute leukemia
• Developing small molecules targeting menin-MLL-LEDGF interaction in leukemia
• Targeting protein-protein interactions using small molecules
• Development of small molecule inhibitors targeting epigenetic modulators in cancer